Welcome to our dedicated page for aTyr Pharma news (Ticker: LIFE), a resource for investors and traders seeking the latest updates and insights on aTyr Pharma stock.
aTyr Pharma, Inc. (NASDAQ: LIFE) is at the forefront of the discovery and clinical development of pioneering medicines targeting severe, rare diseases. Leveraging unique insights into physiocrine biology, a newly identified group of physiological modulators, aTyr aims to deliver breakthrough treatments to patients in need.
The company's flagship candidate, resolaris™, is a first-in-class intravenous protein therapeutic designed to address rare myopathies with an immune component. Resolaris™ is undergoing a series of Phase 1b/2 clinical trials, including trials for adult patients with facioscapulohumeral muscular dystrophy (FSHD), limb girdle muscular dystrophy (LGMD) 2B or FSHD, and patients with an early onset form of FSHD.
aTyr Pharma holds a substantial intellectual property portfolio, featuring 70 issued or allowed patents and over 240 pending patent applications, all of which are solely owned or exclusively licensed by the company. This robust IP estate underpins their strategic focus on severe, rare diseases characterized by immune dysregulation.
One of the company’s notable recent achievements includes the development of efzofitimod, a first-in-class NRP2-targeting immunomodulator. Preclinical models have demonstrated that efzofitimod has significant immune regulatory functions, improving disease outcomes and mitigating fibrosis, particularly in rheumatoid arthritis and associated lung fibrosis.
In addition to its innovative drug pipeline, aTyr Pharma has bolstered its leadership and expertise by enlisting Dr. Frederick to guide corporate affairs and commercial strategies for efzofitimod in interstitial lung disease (ILD).
For the most current updates and detailed information, investors can contact Ashlee Dunston, Director of Investor Relations and Public Affairs, at adunston@atyrpharma.com.
aTyr Pharma, Inc. (Nasdaq: LIFE) announced that the U.S. Patent and Trademark Office has granted a patent for methods using histidyl-tRNA synthetase Fc fusion proteins to reduce inflammatory responses in the lung. This patent pertains to ATYR1923, a candidate in clinical development for pulmonary sarcoidosis and other inflammatory lung diseases. The patent expands aTyr's intellectual property estate, which includes over 220 patents. Results from recent trials show that ATYR1923 may effectively lower inflammatory cytokine levels in patients.
aTyr Pharma (Nasdaq: LIFE) announced that the last patient in its Phase 1b/2a clinical trial of ATYR1923 for pulmonary sarcoidosis has completed their final visit. The trial, involving 37 patients, aims to assess the safety, tolerability, and preliminary efficacy of ATYR1923. Results are anticipated in September 2021. ATYR1923, a fusion protein targeting neuropilin-2, seeks to modulate immune responses in severe inflammatory lung diseases. This milestone is a significant step for aTyr and the sarcoidosis community.
aTyr Pharma, Inc. (Nasdaq: LIFE) will host a virtual Key Opinion Leader event on June 29, 2021, at 5:00 PM ET, featuring Dr. Daniel Culver from the Cleveland Clinic. The discussion will focus on treatment options for pulmonary sarcoidosis, addressing the unmet needs of patients and the challenges of long-term steroid use. aTyr’s lead candidate, ATYR1923, is under evaluation in a Phase 1b/2a study for its safety and efficacy, with data expected in Q3 2021. Attendees will also have the opportunity to engage in a live Q&A session.
aTyr Pharma announced the presentation of its preclinical candidate aNRP2-14 at the Antibody Engineering & Therapeutics Europe Virtual conference, which took place from June 8 to 10, 2021. This antibody selectively blocks Semaphorin 3F/NRP2 signaling pathways linked to immune-mediated diseases, demonstrating significant potential. The findings suggest that aNRP2-14 could serve a therapeutic role, expanding aTyr's pipeline targeting chronic inflammation. This follows the development of their lead candidate, ATYR2810, which is in preclinical trials for cancer.
aTyr Pharma (Nasdaq: LIFE) has appointed Dr. Sara Zaknoen to its Board of Directors. Dr. Zaknoen, with extensive experience in pharmaceutical drug development, previously served as Chief Medical Officer at several biotech firms. This strategic appointment comes as aTyr prepares for the readout of its proof-of-concept study for ATYR1923 in pulmonary sarcoidosis by Q3 2021. The company is also advancing its oncology candidate ATYR2810, targeting Neuropilin-2. Dr. Zaknoen's background is expected to enhance aTyr's clinical development efforts.
aTyr Pharma announced findings related to ATYR2810, a Neuropilin-2 (NRP2) antibody, presented at the Virtual Keystone Symposia on Cancer Stem Cells. The research demonstrates that ATYR2810 effectively blocks the NRP2/VEGF signaling axis, enhancing chemotherapy sensitivity in triple-negative breast cancer (TNBC) models. Notably, ATYR2810 downregulates cancer stem cell and epithelial-mesenchymal transition markers in TNBC samples. These findings underscore the potential of ATYR2810 as a therapeutic candidate in treating aggressive tumors.
aTyr Pharma reported Q1 2021 results, highlighting progress in its clinical trials and research initiatives. The company anticipates data from a Phase 1b/2a trial of ATYR1923 in pulmonary sarcoidosis by Q3 2021. Preclinical data for ATYR2810 showed anti-tumor effects in triple-negative breast cancer and non-small cell lung cancer. As of March 31, 2021, aTyr had $50.6 million in cash and equivalents. The company raised $25.2 million through offerings during Q1 2021 and expects ongoing increases in expenses due to heightened R&D activities.
aTyr Pharma (Nasdaq: LIFE) announced that its Hong Kong subsidiary, Pangu BioPharma, achieved key milestones in a two-year, $750,000 grant from the Hong Kong Government’s Innovation and Technology Commission. The project, in collaboration with the Hong Kong University of Science and Technology, focuses on developing bispecific antibodies targeting Neuropilin-2 (NRP2) for diseases like cancer. The initial year included establishing a research team and implementing a novel antibody discovery approach, yielding promising candidates for therapeutic assays.
aTyr Pharma, Inc. (Nasdaq: LIFE) announced the promotion of Leslie Nangle, Ph.D., to Vice President, Research, on May 11, 2021. Dr. Nangle has been with aTyr since 2007, previously serving as Senior Director and Head of Research. With over 20 years in tRNA synthetase research, she is well-positioned to lead ongoing projects, including the development of ATYR1923, aimed at treating inflammatory lung diseases. aTyr focuses on innovative medicines derived from novel biological pathways, boasting an IP portfolio of over 300 therapeutically relevant proteins.
aTyr Pharma (Nasdaq: LIFE) will report its first quarter 2021 financial results on May 13, 2021, after market close. The management will host a conference call and webcast at 5:00 pm EDT to discuss the results and provide a corporate update. The company specializes in innovative medicines based on biological pathways, focusing on ATYR1923, a candidate for inflammatory lung diseases. For more details, visit aTyr Pharma's website.
FAQ
What is the current stock price of aTyr Pharma (LIFE)?
What is the market cap of aTyr Pharma (LIFE)?
What does aTyr Pharma, Inc. specialize in?
What is aTyr Pharma's leading drug candidate?
In which clinical trial phases is resolaris™ currently?
What is the significance of physiocrine biology for aTyr Pharma?
How strong is aTyr Pharma's intellectual property portfolio?
What is efzofitimod?
Who can investors contact for more information?
What recent strategic addition did aTyr Pharma make?
When will aTyr Pharma's ticker symbol change take effect?
What is the focus of aTyr Pharma's key programs?
